Investigating a protein that contributes to pancreatic cancer and its treatment resistance
Official title: Full Project 2
Funded at University of California Riverside · NIH-10933473 · Data updated 2026-11-12
This study is looking at a protein called PIN1 that is often found in high amounts in pancreatic cancer, and by figuring out how it helps the cancer grow and resist treatment, the researchers hope to create new medicines that can make current treatments work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $212,894 |
| NIH project number | 5U54CA285114-02 |
| Project ID | NIH-10933473 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those who may not respond well to current therapies.
✕Less likely to help
Patients with cancers other than pancreatic cancer or those who are not undergoing chemotherapy may not benefit from this research.
What this research studies
This research focuses on a protein called PIN1, which is found in high levels in pancreatic cancer cells and surrounding tissues. By understanding how PIN1 influences cancer growth and resistance to chemotherapy, the researchers aim to develop new inhibitors that could enhance the effectiveness of existing treatments like gemcitabine. The study employs advanced techniques such as medicinal chemistry and X-ray crystallography to design these inhibitors. Patients may benefit from improved treatment options if these inhibitors prove successful.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Pellecchia, Maurizio — University of California Riverside
- Study coordinator: Pellecchia, Maurizio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.